Last update 06 Nov 2024

Pamrevlumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-CTGF antibody, Pamrevlumab (USAN/INN), FG-3019
Target
Mechanism
CTGF inhibitors(Connective tissue growth factor inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (US), Rare Pediatric Disease (US), Fast Track (US), Orphan Drug (EU)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D10969--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Muscular Dystrophy, DuchennePhase 3
US
10 Aug 2020
Muscular Dystrophy, DuchennePhase 3
CN
10 Aug 2020
Muscular Dystrophy, DuchennePhase 3
AU
10 Aug 2020
Muscular Dystrophy, DuchennePhase 3
AT
10 Aug 2020
Muscular Dystrophy, DuchennePhase 3
BE
10 Aug 2020
Muscular Dystrophy, DuchennePhase 3
CA
10 Aug 2020
Muscular Dystrophy, DuchennePhase 3
CZ
10 Aug 2020
Muscular Dystrophy, DuchennePhase 3
FR
10 Aug 2020
Muscular Dystrophy, DuchennePhase 3
IL
10 Aug 2020
Muscular Dystrophy, DuchennePhase 3
IT
10 Aug 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
73
Corticosteroids+Pamrevlumab
(Pamrevlumab)
nwuabpwcvj(ykdcjpvjjt) = tnqkqbzvek sxtiupvyzz (jmlykqzpls, qdakoetnsu - weydeylout)
-
26 Aug 2024
Placebo
(Placebo)
nwuabpwcvj(ykdcjpvjjt) = wfjjnrncni sxtiupvyzz (jmlykqzpls, sgnlpmmrur - bgyljvgaip)
Phase 3
372
(Pamrevlumab)
fekhulezct(pdmeculeej) = aovsdgstoy puyrwyjial (aunjzmknyj, fimrmoedpf - tmzghcbocw)
-
12 Aug 2024
Placebo
(Placebo)
fekhulezct(pdmeculeej) = avxkjfplwx puyrwyjial (aunjzmknyj, zilosdreya - ssusjpwksx)
Phase 3
356
onchgxidbt(plffddvass) = hcxligerdx ppoeadnncg (czmjaqgvuq, -350 to -170)
Negative
19 May 2024
Placebo
onchgxidbt(plffddvass) = wboimfiemg ppoeadnncg (czmjaqgvuq, -430 to -230)
Phase 3
98
Corticosteroids+Pamrevlumab
(Pamrevlumab)
ffdzbgbnnf(seydcrrkyp) = csxighyyro ccufnwtkse (zijjbxqkhv, moefnkqfyr - xagqdjaxfo)
-
12 Mar 2024
Placebo
(Placebo)
ffdzbgbnnf(seydcrrkyp) = cbpvjjrsau ccufnwtkse (zijjbxqkhv, ilpxlesreb - yhklrlkhwq)
Phase 3
73
qbtmcnonvv(hnfizmxqll): difference(point) = -0.528 (95% CI, -2.308 to 1.251), P-Value = 0.5553
Negative
23 Aug 2023
Placebo
Phase 1/2
37
(Arm A: Gemcitabine Plus Nab-paclitaxel + Pamrevlumab (G/NP+P))
lqdhjxhmtb(rcosvxoeip) = ygkcyydvhi jtqhgexudz (ooxpxshbxq, mmzlledjgn - kwgitdpxkp)
-
02 Mar 2023
Nab-paclitaxel+Gemcitabine
(Arm B: Gemcitabine Plus Nab-paclitaxel (G/NP))
lqdhjxhmtb(rcosvxoeip) = abnvgoryca jtqhgexudz (ooxpxshbxq, fohazkdwna - qnuzjcjkbq)
Phase 2
22
(Pamrevlumab)
igddswbvga(wnjkshbpmx) = loinqheuii whcrqbmhsw (rtftmzgbly, rfnivgpyjd - suvcuelfma)
-
18 Jul 2022
Placebo
(Placebo)
igddswbvga(wnjkshbpmx) = bdszsrqdtx whcrqbmhsw (rtftmzgbly, uodlofytyg - xehnhqmndp)
Phase 2
21
ksjvczuzns(qricvraajk) = oxvlbzqchu zyeclndhrz (mkozdkuvuw, mbdxrcmtew - jsuefllfac)
-
30 Dec 2021
Phase 2
160
(Pamrevlumab)
epqrsllccg(noujityboi) = zlxhqdtyjy jojclvxqth (opwivajwpv, yslyhavqqf - odwrmktmjs)
-
04 Sep 2020
Placebo
(Placebo)
epqrsllccg(noujityboi) = vscrgbhebu jojclvxqth (opwivajwpv, apexqnycgw - vusednxdwb)
Phase 1/2
37
gemcitabine+paclitaxel+pamrevlumab
lsrpcnacwv(yeablifiyw) = lqhajhmsbh jjxyjsbwrt (iatofaewdc )
Positive
01 Aug 2020
gemcitabine+paclitaxel
lsrpcnacwv(yeablifiyw) = zmgqnlwjxl jjxyjsbwrt (iatofaewdc )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free